Haemonetics Co. (NYSE:HAE) Shares Acquired by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P increased its stake in shares of Haemonetics Co. (NYSE:HAE) by 8.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 163,856 shares of the medical instruments supplier’s stock after buying an additional 12,310 shares during the quarter. Loomis Sayles & Co. L P owned about 0.33% of Haemonetics worth $13,171,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its position in shares of Haemonetics by 38.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 562,454 shares of the medical instruments supplier’s stock worth $48,006,000 after acquiring an additional 156,665 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in Haemonetics by 311.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 25,775 shares of the medical instruments supplier’s stock worth $2,132,000 after purchasing an additional 19,510 shares during the last quarter. Global Alpha Capital Management Ltd. acquired a new stake in shares of Haemonetics in the third quarter valued at approximately $806,000. Janus Henderson Group PLC raised its holdings in shares of Haemonetics by 26.8% during the first quarter. Janus Henderson Group PLC now owns 29,730 shares of the medical instruments supplier’s stock valued at $2,536,000 after buying an additional 6,287 shares during the last quarter. Finally, CWM LLC boosted its position in shares of Haemonetics by 40.5% during the second quarter. CWM LLC now owns 36,526 shares of the medical instruments supplier’s stock worth $3,022,000 after buying an additional 10,537 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Trading Up 0.1 %

Shares of NYSE:HAE opened at $88.56 on Wednesday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 1.33 and a beta of 0.32. Haemonetics Co. has a 1-year low of $70.25 and a 1-year high of $97.97. The company has a 50 day moving average price of $79.23 and a 200 day moving average price of $82.24.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.03. The business had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company posted $0.99 EPS. On average, research analysts anticipate that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on HAE. JMP Securities restated a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a research report on Tuesday, August 13th. Citigroup reduced their price objective on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price on the stock in a research note on Friday, November 8th. CL King initiated coverage on shares of Haemonetics in a research note on Friday, September 13th. They issued a “buy” rating and a $116.00 price target for the company. Finally, Bank of America assumed coverage on shares of Haemonetics in a research note on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.